Ipilimumab for Patients with Relapse after Allogeneic Transplantation | Zendy

Matthew S. Davids | Zendy; Haesook T. Kim | Zendy; Pavan Bachireddy | Zendy; Caitlin Costello | Zendy; Rebecca Liguori | Zendy; Alexandra Savell | Zendy; Alexander Lukez | Zendy; David Avigan | Zendy; YiBin Chen | Zendy; Peter A. McSweeney | Zendy; Nicole R. LeBoeuf | Zendy; Michael S. Rooney | Zendy; Michaela Bowden | Zendy; Chensheng W. Zhou | Zendy; Scott R. Granter | Zendy; Jason L. Hornick | Zendy; Scott J. Rodig | Zendy; Masahiro Hirakawa | Zendy; Mariano Severgnini | Zendy; F. Stephen Hodi | Zendy; Catherine J. Wu | Zendy; Vincent T. Ho | Zendy; Corey Cutler | Zendy; John Koreth | Zendy; Edwin P. Alyea | Zendy; Joseph H. Antin | Zendy; Philippe Armand | Zendy; Howard Streicher | Zendy; Edward D. Ball | Zendy; Jerome Ritz | Zendy; Asad Bashey | Zendy; Robert J. Soiffer | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Ipilimumab for Patients with Relapse after Allogeneic Transplantation

Author(s) -

Matthew S. Davids,

Haesook T. Kim,

Pavan Bachireddy,

Caitlin Costello,

Rebecca Liguori,

Alexandra Savell,

Alexander Lukez,

David Avigan,

YiBin Chen,

Peter A. McSweeney,

Nicole R. LeBoeuf,

Michael S. Rooney,

Michaela Bowden,

Chensheng W. Zhou,

Scott R. Granter,

Jason L. Hornick,

Scott J. Rodig,

Masahiro Hirakawa,

Mariano Severgnini,

F. Stephen Hodi,

Catherine J. Wu,

Vincent T. Ho,

Corey Cutler,

John Koreth,

Edwin P. Alyea,

Joseph H. Antin,

Philippe Armand,

Howard Streicher,

Edward D. Ball,

Jerome Ritz,

Asad Bashey,

Robert J. Soiffer

Publication year - 2016

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1601202

Subject(s) - medicine , ipilimumab , hematopoietic stem cell transplantation , adverse effect , myeloid leukemia , transplantation , donor lymphocyte infusion , leukemia , total body irradiation , oncology , immune system , immunosuppression , cancer , gastroenterology , immunology , immunotherapy , chemotherapy , cyclophosphamide

Loss of donor-mediated immune antitumor activity after allogeneic hematopoietic stem-cell transplantation (HSCT) permits relapse of hematologic cancers. We hypothesized that immune checkpoint blockade established by targeting cytotoxic T-lymphocyte-associated protein 4 with ipilimumab could restore antitumor reactivity through a graft-versus-tumor effect.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research